MK-2214, Florquinitau F18, Placebo to MK-2214
MK-2214-004
Phase 2 small_molecule active
Quick answer
MK-2214, Florquinitau F18, Placebo to MK-2214 for Alzheimer’s Disease is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Alzheimer’s Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active